Sponsored Content | Case Study | Proton Therapy | September 07, 2016

Robust Treatment Planning at Europe’s First ProteusOne Center

proton therapy

the proton therapy center at CAL, Nice.


A new proton therapy center at Centre Antoine-Lacassagne (CAL) in Nice, France, will soon begin treating patients with IBA’s ProteusOne system and the RayStation

treatment planning system. The facility is one of only two proton therapy centers in France, and the first in Europe with the ProteusOne, IBA’s compact pencil beam scanning proton therapy system.  

Today, CAL treats around 2,300 patients per year using a wide range of treatment techniques and systems, including photon therapy, TomoTherapy, SBRT, brachytherapy and CyberKnife robotic radiosurgery. With the ProteusOne, the center will also be able to deliver highly precise treatment for pediatric cancers, as well as for complex cases such as cancers of the head and neck or spinal cord. CAL anticipates that its proton therapy center will treat around 250 patients per year when up to speed.

Jérôme Doyen, M.D., a physician at CAL, said that expanding proton therapy capabilities was a natural step. “We felt we had gone as far as possible in improving the quality of photon therapy plans. Proton therapy will enable us to take precision to new levels. We are one of the pioneers in France, but the technology is becoming more accessible, and I am certain this treatment technique will expand to other centers during the next few years,” he said.

The proton therapy technique will enable the center to treat more complex cases, including radioresistant cancers such as chondrosarcomas and chordomas that need high radiation doses, for example up to 74 Gy. It will also make it possible to treat tumors close to organs at risk, for example in the base of the skull, or in areas where surgery is difficult, such as the spinal cord or intestines.

The precision of proton therapy is also valuable when treating children. “Not because we achieve better tumor coverage,” Doyen said, “But to reduce the integral dose to avoid long-term consequences such as radiation-induced cancers. Proton therapy also has been shown to reduce hormonal disorders over the long term. Some 10–20 percent of cancer patients could benefit from proton therapy, such as young adults with Hodgkin’s lymphoma or patients with left-sided breast cancers, among other indications.”

Robust optimization was a key reason for choosing RayStation as the treatment planning system for the new facility. RayStation’s robust optimization method takes geometric and dosimetric uncertainties into account, including interfractional movement and range and positioning uncertainties. It calculates for various possible scenarios, ensuring the plan is effective and accurate even when treatment conditions are not optimal. In proton therapy, this makes it possible to plan the dose for the CTV, instead of the PTV, which is generally used in conventional radiation therapy.

Anais Gerard, a medical physicist at CAL, said, “RayStation is the only commercial treatment planning system that offers this robust optimization. Computation speed is a key component when running multiple scenarios of optimization; RayStation is impressively fast, even when running as many as 21 scenarios for one case.”

Gerard commented that as a pioneering cancer center, it is essential for CAL to ensure the ability to meet future needs. “RayStation is part of our long-term approach. We have a variety of treatment machines, and we needed a treatment planning system that would enable us to plan for all our treatment techniques in the future,” she said. “RaySearch releases new software versions every year that take user requests into account. It is great to work with such a responsive team.”

Another useful feature is RayStation’s scripting capability, which gives the flexibility to personalize the treatment planning system according to the center’s needs and workflow. 

Marie Vidal, a medical physicist at CAL, added that setting up RayStation for the ProteusOne system was more straightforward than expected. “We thought we would have to adjust the beam model when commissioning RayStation for this new synchro-cyclotron technology, but it was a one-shot modeling. We got very good results and high precision on Bragg peak and spot measurements, as well as for flatness, symmetry, penumbra and size of lateral fields.”

Vidal added, “We are also looking forward to running our dose calculations in the Monte Carlo algorithm for particle therapy, which is coming in the next release later this year.”

Related Content

Videos | Radiation Therapy

Jeffrey T. Chapman, a medical student at the University of Texas Southwestern Medical Center, Explains how watching ...

Time November 24, 2021
arrow
News | Nuclear Imaging

November 22, 2021 — IBA, a leader in particle accelerator technology, and NorthStar Medical Radioisotopes LLC, a global ...

Time November 22, 2021
arrow
News | Lung Imaging

November 19, 2021 — Lung cancer screening is recommended only for those who are at high risk for the disease — adults ...

Time November 19, 2021
arrow
News | Artificial Intelligence

November 18, 2021 — Worldwide the most common cause of cancer mortality in 2020 was lung cancer, with an estimated 1.80 ...

Time November 18, 2021
arrow
Videos | Radiopharmaceuticals and Tracers

Ana Kiess, M.D., Ph.D., assistant professor of radiation oncology and molecular radiation sciences, Johns Hopkins ...

Time November 17, 2021
arrow
Videos | Radiation Therapy

The Elekta Harmony radiotherapy system gained FDA clearance in the summer of 2021 and was on display for the first time ...

Time November 17, 2021
arrow
News | Radiation Therapy

November 17, 2021 — Radiation can be a powerful cancer therapy, but it doesn’t work for everyone. A new study identifies ...

Time November 17, 2021
arrow
Videos | Radiation Oncology

This is a model of the Toshiba ion beam radiation therapy system at the American Society of Radiation Oncology (ASTRO) ...

Time November 16, 2021
arrow
News | Breast Imaging

November 16, 2021 — Patients with two out of the three most common types of advanced breast cancer now have an average ...

Time November 16, 2021
arrow
News | Prostate Cancer

November 16, 2021 — A new Harvey L. Neiman Health Policy Institute study of nearly 800,000 men found that between 2011 ...

Time November 16, 2021
arrow
Subscribe Now